Recursion Pharmaceuticals, Inc. in 1 story
The narratives RXRX currently appears in, with its side and exposure in each.
Bull side
0 storiesNo bull-side stories for RXRX yet.
Bear side
1 story- China Becomes Pharma's Global R&D Engine
RXRX in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Recursion must demonstrate that its capital-intensive technology platform can outperform the speed, cost and clinical output increasingly offered by Chinese biotechnology pipelines.